UA111738C2 - Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин - Google Patents
Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітинInfo
- Publication number
- UA111738C2 UA111738C2 UAA201312611A UAA201312611A UA111738C2 UA 111738 C2 UA111738 C2 UA 111738C2 UA A201312611 A UAA201312611 A UA A201312611A UA A201312611 A UAA201312611 A UA A201312611A UA 111738 C2 UA111738 C2 UA 111738C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cancer
- tumor cells
- tiscodine
- high hydrostatic
- active
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 210000004881 tumor cell Anatomy 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 230000002706 hydrostatic effect Effects 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000009931 pascalization Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4275—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oncology (AREA)
- Mycology (AREA)
Abstract
Винахід стосується фармацевтичної композиції для викликання імунної реакції проти пухлинних клітин, що включає пухлинні клітини, приведені в апоптотичний стан шляхом обробки високим гідростатичним тиском, і дендритні клітини. Винахід стосується способу одержання даної композиції та способу лікування людини шляхом протиракової вакцинації.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11172622A EP2543386A1 (en) | 2011-07-05 | 2011-07-05 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure |
| PCT/EP2012/062950 WO2013004708A1 (en) | 2011-07-05 | 2012-07-04 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA111738C2 true UA111738C2 (uk) | 2016-06-10 |
Family
ID=44359435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201312611A UA111738C2 (uk) | 2011-07-05 | 2012-04-07 | Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20140086957A1 (uk) |
| EP (2) | EP2543386A1 (uk) |
| JP (1) | JP5986196B2 (uk) |
| KR (1) | KR102035873B1 (uk) |
| CN (3) | CN103648524B (uk) |
| AU (2) | AU2012280322B2 (uk) |
| BR (2) | BR112013031084B1 (uk) |
| CA (1) | CA2833946A1 (uk) |
| DK (1) | DK2691110T3 (uk) |
| EA (1) | EA030061B1 (uk) |
| ES (1) | ES2525759T3 (uk) |
| PH (1) | PH12013502462B1 (uk) |
| PL (1) | PL2691110T3 (uk) |
| PT (1) | PT2691110E (uk) |
| RS (1) | RS53713B1 (uk) |
| RU (1) | RU2012127685A (uk) |
| SG (1) | SG194201A1 (uk) |
| SI (1) | SI2691110T1 (uk) |
| SM (1) | SMT201400188B (uk) |
| UA (1) | UA111738C2 (uk) |
| WO (1) | WO2013004708A1 (uk) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130011438A1 (en) | 2011-07-05 | 2013-01-10 | SOTIO a.s. | Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells |
| US9562219B2 (en) * | 2013-12-27 | 2017-02-07 | SOTIO a.s. | Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer |
| CN104258384B (zh) * | 2014-09-29 | 2017-05-03 | 北京时合生物科技有限公司 | 一种基于树突状细胞的特异性肿瘤疫苗的制备方法 |
| CA2991212A1 (en) * | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
| CN106244543A (zh) * | 2016-07-29 | 2016-12-21 | 北京时合生物科技有限公司 | 一种pbmc体外诱导分化成为树突状细胞的方法 |
| JP2020507616A (ja) * | 2017-02-17 | 2020-03-12 | アイビタ バイオメディカル インコーポレイテッド | 改変された腫瘍細胞および改変された樹状細胞を使用して、腫瘍免疫原性を増強する方法および自己癌免疫療法製品の組成物 |
| WO2019101110A1 (zh) * | 2017-11-21 | 2019-05-31 | 中国科学院上海药物研究所 | 天花粉蛋白用于致敏和/激活树突状细胞中的应用 |
| WO2019145469A1 (en) | 2018-01-25 | 2019-08-01 | SOTIO a.s. | Dendritic cell vaccination sequential to chemotherapy |
| US20210060146A1 (en) | 2018-01-25 | 2021-03-04 | SOTIO a.s. | Dendritic cell vaccination in parallel to chemotherapy |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020187975A1 (en) | 2019-03-19 | 2020-09-24 | SOTIO a.s. | Patient selection for treatment with dendritic cell vaccination |
| JP7340240B2 (ja) * | 2019-08-26 | 2023-09-07 | 学校法人関西医科大学 | 細胞又は組織にアポトーシスを誘導する方法 |
| WO2022171792A1 (en) | 2021-02-12 | 2022-08-18 | Sctbio A.S. | Patient selection for treatment with dendritic cell vaccination |
| EP4384204A1 (en) | 2021-08-13 | 2024-06-19 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN114807229B (zh) * | 2022-05-27 | 2024-09-24 | 中国科学院长春应用化学研究所 | 细胞膜、纳米疫苗及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2321093A1 (en) * | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
| WO2006047515A2 (en) | 2004-10-25 | 2006-05-04 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| WO2006095330A2 (en) * | 2005-03-10 | 2006-09-14 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
| KR100647847B1 (ko) | 2005-05-27 | 2006-11-23 | 크레아젠 주식회사 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 |
-
2011
- 2011-07-05 EP EP11172622A patent/EP2543386A1/en not_active Withdrawn
-
2012
- 2012-04-07 UA UAA201312611A patent/UA111738C2/uk unknown
- 2012-07-03 RU RU2012127685/15A patent/RU2012127685A/ru unknown
- 2012-07-04 WO PCT/EP2012/062950 patent/WO2013004708A1/en not_active Ceased
- 2012-07-04 AU AU2012280322A patent/AU2012280322B2/en active Active
- 2012-07-04 CN CN201280032974.7A patent/CN103648524B/zh active Active
- 2012-07-04 PH PH1/2013/502462A patent/PH12013502462B1/en unknown
- 2012-07-04 SI SI201230120T patent/SI2691110T1/sl unknown
- 2012-07-04 EP EP12734884.5A patent/EP2691110B1/en active Active
- 2012-07-04 PT PT127348845T patent/PT2691110E/pt unknown
- 2012-07-04 PL PL12734884T patent/PL2691110T3/pl unknown
- 2012-07-04 JP JP2014517778A patent/JP5986196B2/ja active Active
- 2012-07-04 SG SG2013077128A patent/SG194201A1/en unknown
- 2012-07-04 KR KR1020137032259A patent/KR102035873B1/ko active Active
- 2012-07-04 CN CN201810985605.9A patent/CN109125347A/zh active Pending
- 2012-07-04 EA EA201301089A patent/EA030061B1/ru unknown
- 2012-07-04 CN CN2012102924999A patent/CN102861103A/zh active Pending
- 2012-07-04 DK DK12734884.5T patent/DK2691110T3/en active
- 2012-07-04 BR BR112013031084-7A patent/BR112013031084B1/pt active IP Right Grant
- 2012-07-04 ES ES12734884.5T patent/ES2525759T3/es active Active
- 2012-07-04 RS RS20140685A patent/RS53713B1/sr unknown
- 2012-07-04 CA CA2833946A patent/CA2833946A1/en active Pending
- 2012-07-04 BR BR122019026627-1A patent/BR122019026627B1/pt active IP Right Grant
- 2012-07-04 US US14/113,337 patent/US20140086957A1/en not_active Abandoned
-
2014
- 2014-12-17 SM SM201400188T patent/SMT201400188B/xx unknown
-
2016
- 2016-09-28 AU AU2016234915A patent/AU2016234915B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA111738C2 (uk) | Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин | |
| AU2018256508A1 (en) | Individualized vaccines for cancer | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
| CL2016002088A1 (es) | Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica. | |
| MX374547B (es) | Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer. | |
| MX2017017079A (es) | Sistema de administracion dirigida de principio activo celular. | |
| IN2014CN04251A (uk) | ||
| PH12013501636A1 (en) | Treatment of osteoarthritis and pain | |
| GB201118656D0 (en) | New compounds | |
| AR078247A1 (es) | Vacuna de pcsk9 | |
| TN2014000206A1 (en) | Antibody molecules having specificity for human ox40 | |
| EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| WO2013028942A8 (en) | Targeting microbubbles | |
| MX377157B (es) | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. | |
| MX2021015735A (es) | Composiciones de nucleasa terapeuticas y metodos. | |
| MX349321B (es) | Terapia combinada. | |
| NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
| EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
| WO2011100769A3 (en) | Kinase modulators for the treatment of cancer | |
| EP4233896A3 (en) | Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells | |
| CY1115803T1 (el) | Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| EA201792560A1 (ru) | Наночастицы для применения в качестве терапевтической вакцины | |
| WO2014100857A8 (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |